4.6 Article

HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV

期刊

JOURNAL OF VIROLOGY
卷 95, 期 4, 页码 -

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01622-20

关键词

HTCC; MERS; SARS-CoV-2; chitosan; coronaviridae; coronavirus; entry; inhibitor; inhibition

类别

资金

  1. Polish Ministry of Science and Higher Education
  2. National Science Center [UMO2017/27/B/NZ6/02488]
  3. EU-Horizon2020 ITN OrganoVir grant [812673]

向作者/读者索取更多资源

The compound HTCC has been found to have broad-spectrum antiviral activity, effectively blocking MERS-CoV and SARS-CoV-2 infections; the polymer acts by interacting with the S protein to prevent virus entry into host cells.
Among seven coronaviruses that infect humans, three (severe acute respiratory syndrome coronavirus [SARS-CoV], Middle East respiratory syndrome coronavirus [MERS-CoV], and the newly identified severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) are associated with a severe, life-threatening respiratory infection and multiorgan failure. We previously proposed that the cationically modified chitosan N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC) is a potent inhibitor of human coronavirus NL63 (HCoV-NL63). Next, we demonstrated the broad-spectrum antiviral activity of the compound, as it inhibited all low -pathogenicity human coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1). Here, using in vitro and ex vivo models of human airway epithelia, we show that HTCC effectively blocks MERS-CoV and SARS-CoV-2 infection. We also confirmed the mechanism of action for these two viruses, showing that the polymer blocks the virus entry into the host cell by interaction with the S protein. IMPORTANCE The beginning of 2020 brought us information about the novel corona virus emerging in China. Rapid research resulted in the characterization of the pathogen, which appeared to be a member of the SARS-like cluster, commonly seen in bats. Despite the global and local efforts, the virus escaped the health care measures and rapidly spread in China and later globally, officially causing a pandemic and global crisis in March 2020. At present, different scenarios are being written to contain the virus, but the development of novel anticoronavirals for all highly pathogenic coronaviruses remains the major challenge. Here, we describe the antiviral activity of an HTCC compound, previously developed by us, which may be used as a potential inhibitor of currently circulating highly pathogenic coronaviruses-SARSCoV-2 and MERS-CoV.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据